Biomarin Pharmaceutical (BMRN) Change in Receivables (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Change in Receivables came in at $7.2 million in Q1 2026, down 87.57% YoY from $57.6 million in Q1 2025, and down 94.07% on a QoQ basis from $120.7 million in Q4 2025.
Biomarin Pharmaceutical (BMRN) Change in Receivables (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Change in Receivables data on file, last reported at $7.2 million in Q1 2026.
- Quarterly Change in Receivables fell 87.57% year-over-year to $7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $177.6 million (up 58.43% YoY) and the FY2025 annual result came in at $228.1 million, up 293.81% from the prior year.
- Change in Receivables declined to $7.2 million in Q1 2026, from $120.7 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $138.8 million in Q1 2023 to a low of -$72.5 million in Q4 2024.
- A 5-year average of $33.3 million and a median of $37.7 million in 2022 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables jumped 46462.3% — and 2024, when it tumbled 224.02%.
- Tracing BMRN's Change in Receivables over 5 years: stood at $28.3 million in 2022, then soared by 106.83% to $58.5 million in 2023, then plunged by 224.02% to -$72.5 million in 2024, then surged by 266.34% to $120.7 million in 2025, then plunged by 94.07% to $7.2 million in 2026.
- The last three Change in Receivables figures came in at $7.2 million (Q1 2026), $120.7 million (Q4 2025), and -$48.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 38.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.85 Mn |
| Jun 30, 2026 | 38.85 Mn |
| Mar 31, 2026 | 7.16 Mn |
| Mar 31, 2026 | 7.16 Mn |
| Dec 31, 2025 | 120.68 Mn |
| Dec 31, 2025 | 120.68 Mn |
| Sep 30, 2025 | -48.75 Mn |
| Sep 30, 2025 | -48.75 Mn |
| Jun 30, 2025 | 98.53 Mn |
| Jun 30, 2025 | 98.53 Mn |
| Mar 31, 2025 | 57.59 Mn |
| Mar 31, 2025 | 57.59 Mn |
| Dec 31, 2024 | -72.55 Mn |
| Dec 31, 2024 | -72.55 Mn |
| Sep 30, 2024 | 74.38 Mn |
| Sep 30, 2024 | 74.38 Mn |
| Jun 30, 2024 | 52.70 Mn |
| Jun 30, 2024 | 52.70 Mn |
| Mar 31, 2024 | 3.39 Mn |
| Mar 31, 2024 | 3.39 Mn |